Adhera Therapeutics (Worldwide License to Tolimidone) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Adhera Therapeutics (Worldwide License to Tolimidone) General Information

Description

Portfolio of a license to diabetic drug development in Industry, California. The asset is a selective activator of the enzyme Lyn kinase which increases phosphorylation of insulin substrate -1 and diabetic treatments.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Industry, CA
  • United States
Primary Industry
Buildings and Property
Other Industries
Drug Discovery
Acquirer
Biodexa Pharmaceuticals
Corporate Office
  • Industry, CA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Adhera Therapeutics (Worldwide License to Tolimidone) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Adhera Therapeutics (Worldwide License to Tolimidone)‘s full profile, request access.

Request a free trial

Adhera Therapeutics (Worldwide License to Tolimidone) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Adhera Therapeutics (Worldwide License to Tolimidone)‘s full profile, request access.

Request a free trial

Adhera Therapeutics (Worldwide License to Tolimidone) FAQs

  • Where is Adhera Therapeutics (Worldwide License to Tolimidone) headquartered?

    Adhera Therapeutics (Worldwide License to Tolimidone) is headquartered in Industry, CA.

  • What industry is Adhera Therapeutics (Worldwide License to Tolimidone) in?

    Adhera Therapeutics (Worldwide License to Tolimidone)’s primary industry is Buildings and Property.

  • Is Adhera Therapeutics (Worldwide License to Tolimidone) a private or public company?

    Adhera Therapeutics (Worldwide License to Tolimidone) is a Private company.

  • What is Adhera Therapeutics (Worldwide License to Tolimidone)’s current revenue?

    The current revenue for Adhera Therapeutics (Worldwide License to Tolimidone) is .

  • Who are Adhera Therapeutics (Worldwide License to Tolimidone)’s investors?

    Adhera Therapeutics (Acquired) has invested in Adhera Therapeutics (Worldwide License to Tolimidone).

  • When was Adhera Therapeutics (Worldwide License to Tolimidone) acquired?

    Adhera Therapeutics (Worldwide License to Tolimidone) was acquired on 21-Dec-2023.

  • Who acquired Adhera Therapeutics (Worldwide License to Tolimidone)?

    Adhera Therapeutics (Worldwide License to Tolimidone) was acquired by Biodexa Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process